Trials / Unknown
UnknownNCT00268684
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
A Phase III Trial Comparing Whole Brain Radiation (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 381 (planned)
- Sponsor
- Tel-Aviv Sourasky Medical Center · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of the study is to determine if either temozolomide or erlotinib combined with WBRT and SRS improves survival as compared to WBRT and SRS alone.Ptients with histologically confirmed NSCLC with the presence of 1-3 intraparenchymal brain metastases will be randomized to 3 arms. All of the patients will receive WBRT and SRS. The patients of the arm 1 will receive radiation treatment only, the arm 2 patients will be treated with temozolomide and arm 3 patients will receive erlotinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib, Temozolomide |
Timeline
- Start date
- 2005-05-01
- First posted
- 2005-12-22
- Last updated
- 2006-02-28
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00268684. Inclusion in this directory is not an endorsement.